Press Releases
Read the latest announcements from Beactica Therapeutics
Beactica Therapeutics’ TEAD programme selected for late-breaking research presentation at the AACR Annual Meeting 2024
Uppsala, Sweden – 14 February 2024
Read more
Beactica Therapeutics announces collaboration with the National Center for Advancing Translational Sciences
Uppsala, Sweden – 26 Sep 2023
Read more
Beactica Therapeutics strengthens its preclinical development team
Uppsala, Sweden – 12 Sep 2023
Read more
Beactica Therapeutics announces the selection of BEA-17 as a preclinical candidate
Uppsala, Sweden – 5 Sep 2023
Read more
Beactica Therapeutics appoints Jarl Ulf Jungnelius M.D. to its Board of Directors as it advances towards clinical-stage activities
Uppsala, Sweden – 19 June 2023
Read more
Beactica Therapeutics to present breakthrough in YAP–TEAD programme at the Hippo Pathway Drug Development Summit 2023
Uppsala, Sweden – 16 May 2023
Read more
Beactica Therapeutics to present update on LSD1 programme at the AACR Annual Meeting 2023
Uppsala, Sweden – 11 April 2023
Read more
Beactica Therapeutics and Oscotec mutually agree to conclude oncology collaboration
Uppsala, Sweden and Seoul, South Korea – 4 April 2023
Read more
Beactica Therapeutics receives FDA Orphan Drug Designation for BEA-17 for the treatment of glioblastoma
Uppsala, Sweden – 1 February 2023
Read more
Dong-A ST and Beactica Therapeutics mutually agree to conclude oncology collaboration
Seoul, South Korea and Uppsala, Sweden – 6 September 2022
Read more
Beactica Therapeutics appoints Head of Chemistry and two new members to its Board of Directors to strengthen its strategic focus on cancer
Uppsala, Sweden – 14 september 2021
Read more
Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug
Seoul, South Korea and Uppsala, Sweden – 2 March 2021
Read more
Beactica Therapeutics and University of Dundee announce collaboration to develop WRN inhibitors to target cancer
Uppsala, Sweden and Dundee, Scotland – 12 January 2021
Read more
Dong-A ST and Beactica Therapeutics achieve key milestone in their collaboration to develop new cancer treatments
Seoul, South Korea and Uppsala, Sweden – 4 December 2019
Read more
Beactica Therapeutics participates in innovative training network on targeted protein degradation
Uppsala, Sweden – 30 October 2019
Read more
Beactica Therapeutics appoints several high-profile people to strengthen its strategic focus on drug discovery
Uppsala, Sweden – 10 September 2019
Read more
Beactica wins grant to develop combination therapy for glioblastoma
Uppsala, Sweden – 18 June 2019
Read more
Beactica secures another round of financing as novel glioblastoma treatment advances towards pre-clinical development
Uppsala, Sweden – 4 June 2019
Read more
Dong-A ST and Beactica expand their research and license agreement to develop new cancer treatments
Seoul, South Korea and Uppsala, Sweden – 12 March 2019
Read more
Beactica, VIB and CD3 announce drug discovery alliance targeting inflammatory diseases
Uppsala, Sweden – 27 February 2019
Read more
Beactica to present LSD1 programme at the AACR Annual Meeting 2019
Uppsala, Sweden – 29 January 2019
Read more
Beactica closes financing round to accelerate its pipeline of novel cancer therapeutics
Uppsala, Sweden – 28 August 2018
Read more
Beactica wins European Horizon 2020 innovation grant for project targeting aggressive brain tumours
Uppsala, Sweden – 18 April 2018
Read more
Beactica signs five-year framework agreement with global pharmaceutical company
Uppsala, Sweden – 6 March 2018
Read more
Beactica awarded funding to develop new therapeutics against aggressive brain tumours
Uppsala, Sweden – 22 November 2017
Read more
Beactica advances its oncology pipeline with new investments and appoints Erik Walldén and Uli Hacksell to its Board of Directors
Uppsala, Sweden – 6 November 2017
Read more
Beactica to present at the 15th Annual Discovery On Target Conference in Boston, MA
Uppsala, Sweden – 20 September 2017
Read more
Beactica announces glioblastoma research collaboration with Uppsala University and the DDD Platform at SciLifeLab
Uppsala, Sweden – 16 May 2017
Read more
Dong-A ST and Beactica announce licence and collaboration agreement to develop new cancer treatments
Seoul, South Korea and Uppsala, Sweden – 26 October 2016
Read more
Beactica participates in EU training network on fragment-based drug discovery
Uppsala, Sweden, 12 October 2016
Read more
Beactica Appoints Dr Ulf Bremberg as Chief Scientific Officer
Uppsala, Sweden, 8 September 2015
Read more
Beactica scientists publish strategies for discovery of allosteric modulators
Uppsala, Sweden, 26 May 2015
Read more
Beactica closes financing round successfully to progress epigenetic drug discovery programmes
Uppsala, Sweden, 15 December 2014
Read more
Beactica awarded funding to develop epigenetic cancer drugs
Uppsala, Sweden, 20 November 2014
Read more
Beactica appoints Magnus Björsne to its Board of Directors
Uppsala, Sweden, 18 November 2014
Read more
Beactica receives CIR (French Research Tax Credit) accreditation
Uppsala, Sweden, 11 November 2014
Read more
Beactica initiates drug discovery collaboration with Medivir
Uppsala, Sweden, 10 June 2014
Read more
Beactica expands its drug discovery collaboration with Boehringer Ingelheim
Uppsala, Sweden, 22 October 2013
Read more
Beactica extends fragment-based discovery research services agreement
Uppsala, Sweden, 28 November 2012
Read more
Beactica contributes to detailed understanding of innovative cancer drug
Uppsala, Sweden, 29 October 2012
Read more
Beactica scientists describe methodological advances for the discovery of drugs targeting ion channels
Uppsala, Sweden, June 26th, 2012
Read more
Beactica and Almac Discovery announce their first fragment-based drug discovery agreement
Uppsala, Sweden, December 6th, 2011
Read more
Beactica celebrated as Sweden’s fastest growing young biotech at Deloitte’s “Technology Rising Star” awards
Uppsala, Sweden - November 24th, 2011
Read more
11 nov 2011
Beactica nominated as “Technology Rising Star” by Deloitte
Uppsala, Sweden, November 11, 2011
Read more
27 apr 2011
Beactica announces fragment-based drug discovery agreement
Uppsala, Sweden, April 27th, 2011
Read more
22 feb 2011
Beactica awarded €0.7 million from EU for pioneering influenza research
Uppsala, Sweden, February 22, 2011
Read more
04 feb 2011
Beactica scientists describe strategies for fragment-based drug discovery in two publications in Journal of Medicinal Chemistry
Uppsala, Sweden, February 4, 2011
Read more
14 dec 2010
Beactica announces the appointment of a new Chairman and a new Member to its Board
Uppsala, Sweden, December 14th, 2010
Read more
02 nov 2010
Beactica increases its capacity to address complex research challenges with a Biacore 4000
Uppsala, Sweden, November 2nd, 2010
Read more
12 okt 2010
Beactica scientists reveal novel strategies for discovery of drugs targeting ion channels involved in synaptic signalling
Uppsala, Sweden, October 12th, 2010
Read more
03 sep 2010
Beactica appoints Dr Evert Homan as Chief Operating Officer
Uppsala, Sweden, September 3rd, 2010
Read more
09 aug 2010
03 feb 2010
29 jan 2010
Beactica welcomes Innovationsbron as a new shareholder
Uppsala, Sweden, January 29th, 2010
Read more
13 jan 2010
27 nov 2009
Beactica announces its participation in a Marie Curie Initial Training Network
Uppsala, Sweden, November 27th, 2009
Read more
26 maj 2009
Beactica announces drug discovery agreement with Cubist Pharmaceuticals
Uppsala, Sweden, May 26th, 2009
Read more
13 jan 2009
Beactica announces fragment-based drug discovery research collaboration with GE Healthcare and Uppsala University
Uppsala, Sweden, January 13th, 2009
Read more
15 aug 2008
Beactica welcomes Uppsala University Holding Company as a new shareholder
Uppsala, Sweden, August 15th, 2008
Read more
24 apr 2008
Beactica announces new fragment-based drug discovery platform together with IOTA Pharmaceuticals
Uppsala, Sweden, April 24th, 2008
Read more
12 nov 2007
Beactica announces drug discovery collaboration with Arrow Therapeutics
Uppsala, Sweden, November 12th, 2007
Read more
01 nov 2007
14 sep 2007
Beactica double winner in EU-financed drug discovery projects
Uppsala, Sweden – September 14th, 2007
Read more
07 jun 2007
Beactica receives continued funding from Innovationsbron Uppsala to develop its business
Sweden, June 7, 2007
Read more
02 apr 2007
Beactica receives funding from the Swedish Governmental Agency for Innovation Systems (VINNOVA) to establish a European drug discovery project
Sweden, April 2, 2007
Read more
26 nov 2006
Beactica receives funding from ALMI Företagspartner to develop its technology platform
Sweden, November 22, 2006
Read more
08 okt 2006
Beactica wins business competition organised by the Swedish Governmental Agency for Innovation Systems (VINNOVA) and receives funding
Sweden, October 8, 2006
Read more
05 okt 2006
Beactica receives funding from Innovationsbron Uppsala to develop its technology platform
Uppsala, Sweden, October 5, 2006
Read more
19 sep 2006
Beactica receives funding from Uppsala University Holding Company to develop its technology platform.
Uppsala, Sweden, September 19th, 2006
Read more
25 aug 2006
Beactica is founded in Uppsala by Dr Per Källblad, previously at Medivir AB, and Professor Helena Danielson at Uppsala University.
Uppsala, Sweden, August 25th, 2006
Read moreStay Updated
Sign up for the Beactica newsletter to receive our latest news and updates